Drugmakers including Roche Holding, GlaxoSmithKline, Eli Lilly & Co., Biogen Idec, Gilead Sciences and Novo Nordisk are advancing drugs that could turn out to be blockbusters. But profits might be tempered as insurers and governments increasingly balk at paying high prices for new drugs, says PricewaterhouseCoopers' Simon Friend.

Full Story:

Related Summaries